Funding for this research was provided by Mylan Inc. Acknowledgements We thank Dr Ruth B Murray (Medscript NZ Ltd) for assistance in drafting and editing this manuscript.Peer reviewedPublisher PD
Background: Allergic Rhinitis (AR) is a high-prevalence disease. In Europe about 25% of the general ...
International audienceThe efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochl...
Background and objective: the global prevalence of allergic rhinitis (AR) is rising and yet there is...
ObjectiveThe aims of this survey were to (1) assess the burden of allergic rhinitis (AR) from the pa...
Acknowledgements We would like to thank the subjects who participated in the trial. Funding This stu...
Background: The European Union has prioritized allergic rhinitis (AR) control. Contre les Maladies C...
OBJECTIVE: The aims of this study were (1) to characterise the type of patient prescribed MP-AzeFlu ...
Funding Funding for this survey was provided by Meda Pharma.Peer reviewedPublisher PD
International audienceAllergic rhinitis (AR) is prevalent, and many patients present with moderate-t...
Background: MP-AzeFlu (Dymista (R); spray of azelastine/fluticasone propionate) is the most effectiv...
Objective: Patient and physician perceptions of the effectiveness of treatment, symptoms, and the im...
Background: Allergic rhinitis (AR) has high prevalence and substantial socio-economic burden. Mater...
Background: This article summarizes a EUFOREA symposium, presented during the European Rhinology Res...
Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating ...
Cingi, Cemal/0000-0003-3934-5092WOS: 000434471200007PubMed: 29423374Background: Allergic rhinitis (A...
Background: Allergic Rhinitis (AR) is a high-prevalence disease. In Europe about 25% of the general ...
International audienceThe efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochl...
Background and objective: the global prevalence of allergic rhinitis (AR) is rising and yet there is...
ObjectiveThe aims of this survey were to (1) assess the burden of allergic rhinitis (AR) from the pa...
Acknowledgements We would like to thank the subjects who participated in the trial. Funding This stu...
Background: The European Union has prioritized allergic rhinitis (AR) control. Contre les Maladies C...
OBJECTIVE: The aims of this study were (1) to characterise the type of patient prescribed MP-AzeFlu ...
Funding Funding for this survey was provided by Meda Pharma.Peer reviewedPublisher PD
International audienceAllergic rhinitis (AR) is prevalent, and many patients present with moderate-t...
Background: MP-AzeFlu (Dymista (R); spray of azelastine/fluticasone propionate) is the most effectiv...
Objective: Patient and physician perceptions of the effectiveness of treatment, symptoms, and the im...
Background: Allergic rhinitis (AR) has high prevalence and substantial socio-economic burden. Mater...
Background: This article summarizes a EUFOREA symposium, presented during the European Rhinology Res...
Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating ...
Cingi, Cemal/0000-0003-3934-5092WOS: 000434471200007PubMed: 29423374Background: Allergic rhinitis (A...
Background: Allergic Rhinitis (AR) is a high-prevalence disease. In Europe about 25% of the general ...
International audienceThe efficacy of MP29-02 (a novel intranasal formulation of azelastine hydrochl...
Background and objective: the global prevalence of allergic rhinitis (AR) is rising and yet there is...